Taysha Gene Therapies Files 8-K
Ticker: TSHA · Form: 8-K · Filed: Mar 19, 2024 · CIK: 1806310
Sentiment: neutral
Topics: financial-reporting, operations-update
TL;DR
Taysha Gene Therapies dropped an 8-K on 3/19 detailing financials and operations.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K on March 19, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing provides an update on the company's business and financial status.
Why It Matters
This filing provides crucial updates on Taysha Gene Therapies' financial health and operational status, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing providing financial and operational updates, not indicating immediate significant risk or opportunity.
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- March 19, 2024 (date) — Date of Report
- 3000 Pegasus Park Drive, Suite 1430 Dallas, Texas 75247 (address) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The 8-K indicates that the filing pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', suggesting a comprehensive financial update.
When was this 8-K filed?
The filing date for this 8-K is March 19, 2024.
What is the primary business of Taysha Gene Therapies, Inc.?
Taysha Gene Therapies, Inc. is in the business of 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' as indicated by its Standard Industrial Classification code [2836].
Where are Taysha Gene Therapies, Inc.'s principal executive offices located?
The principal executive offices are located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
What is the fiscal year end for Taysha Gene Therapies, Inc.?
The fiscal year end for Taysha Gene Therapies, Inc. is December 31.
Filing Stats: 537 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-03-19 16:17:03
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value TSHA The Nasdaq Stock Mar
Filing Documents
- d790281d8k.htm (8-K) — 25KB
- d790281dex991.htm (EX-99.1) — 87KB
- 0001193125-24-071321.txt ( ) — 249KB
- tsha-20240319.xsd (EX-101.SCH) — 3KB
- tsha-20240319_lab.xml (EX-101.LAB) — 18KB
- tsha-20240319_pre.xml (EX-101.PRE) — 11KB
- d790281d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Taysha Gene Therapies, Inc. Dated: March 19, 2024 By: /s/ Kamran Alam Kamran Alam Chief Financial Officer